메뉴 건너뛰기
Journal of Clinical Oncology
Volumn 32, Issue 17, 2014, Pages 1857-1859
Reply to R. Bhargava et al and K. Lambein et al
Author keywords

[No Author keywords available]
Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;
EID: 84905868455     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.55.0673     Document Type: Letter
Times cited : (4)
References (6)
  • 1
    • 84905852654 scopus 로고    scopus 로고
    • 2013 Update of the American Society of Clinical Oncology/College of American Pathologists guideline for human epidermal growth factor receptor 2 testing: Impact on immunohistochemistrynegative breast cancers
    • Lambein K, Van Bockstal M, Denys H, et al: 2013 update of the American Society of Clinical Oncology/College of American Pathologists guideline for human epidermal growth factor receptor 2 testing: Impact on immunohistochemistrynegative breast cancers. J Clin Oncol 32:1856-1857, 2014
    • (2014) J Clin Oncol , vol.32 , pp. 1856-1857
    • Lambein, K.1    Van Bockstal, M.2    Denys, H.3
  • 2
    • 84890254448 scopus 로고    scopus 로고
    • Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update
    • Wolff AC, Hammond ME, Hicks DG, et al: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997-4013, 2013
    • (2013) J Clin Oncol , vol.31 , pp. 3997-4013
    • Wolff, A.C.1    Hammond, M.E.2    Hicks, D.G.3
  • 3
    • 84893694960 scopus 로고    scopus 로고
    • Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update
    • Wolff AC, Hammond ME, Hicks DG, et al: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med 138:241-256, 2014
    • (2014) Arch Pathol Lab Med , vol.138 , pp. 241-256
    • Wolff, A.C.1    Hammond, M.E.2    Hicks, D.G.3
  • 4
    • 84884927317 scopus 로고    scopus 로고
    • Distinguishing score 0 from score 1- in HER2 immunohistochemistry- negative breast cancer: Clinical and pathobiological relevance
    • Lambein K, Van Bockstal M, Vandemaele L, et al: Distinguishing score 0 from score 1- in HER2 immunohistochemistry-negative breast cancer: Clinical and pathobiological relevance. Am J Clin Pathol 140:561-566, 2013
    • (2013) Am J Clin Pathol , vol.140 , pp. 561-566
    • Lambein, K.1    Van Bockstal, M.2    Vandemaele, L.3
  • 5
    • 84905828649 scopus 로고    scopus 로고
    • Interpretation of human epidermal growth factor receptor 2 (HER2) In situ hybridization assays using 2013 update of American Society of Clinical Oncology/College of American Pathologists HER2 guidelines
    • Bhargava R, Dabbs DJ: Interpretation of human epidermal growth factor receptor 2 (HER2) In situ hybridization assays using 2013 update of American Society of Clinical Oncology/College of American Pathologists HER2 guidelines. J Clin Oncol 32:1855, 2014
    • (2014) J Clin Oncol , vol.32 , pp. 1855
    • Bhargava, R.1    Dabbs, D.J.2
  • 6
    • 84864141239 scopus 로고    scopus 로고
    • Re: Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria
    • Wolff AC, Hammond ME, Hayes DF: Re: Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. J Natl Cancer Inst 104:957-958, 2012
    • (2012) J Natl Cancer Inst , vol.104 , pp. 957-958
    • Wolff, A.C.1    Hammond, M.E.2    Hayes, D.F.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.